Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy

References

• World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2019. World Health Organization; 2020.
   Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Respirology. 2017;22(3):575–601. doi:10.1111/resp.13012
   PubMed Web of Science ®Google Scholar
• Duan KI, Birger M, Au DH, Spece LJ, Feemster LC, and Dieleman JL. US health care spending on respiratory diseases, 1996–2016. Am J Respir Crit Care Med. 2022. doi:10.1164/rccm.202202-0238LE
   PubMedGoogle Scholar
• Martinez CH, Murray S, Barr RG, et al. Respiratory symptoms items from the COPD assessment test identify ever-smokers with preserved lung function at higher risk for poor respiratory outcomes. An analysis of the subpopulations and intermediate outcome measures in COPD study cohort. Ann Am Thorac Soc. 2017;14(5):636–642. doi:10.1513/AnnalsATS.201610-815OC
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Roman-Rodriguez M, Singh D, Han MK, Rodriguez-Roisin R, and Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir Med. 2020;166:105938. doi:10.1016/j.rmed.2020.105938
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2022 Report. Global Initiative for Chronic Obstructive Lung Disease; 2022.
   Google Scholar
• The global strategy for prevention, diagnosis and management of COPD (updated 2020). The GOLD Report. 2020. Available from: www.goldcopd.org.
   Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American college of physicians, American college of chest physicians, American thoracic society, and European respiratory society. Ann Intern Med. 2011;155(3):179–191. doi:10.7326/0003-4819-155-3-201108020-00008
   PubMed Web of Science ®Google Scholar
• Cardoso J, Coelho R, Rocha C, Coelho C, Semedo L, and Bugalho Almeida A. Prediction of severe exacerbations and mortality in COPD: the role of exacerbation history and inspiratory capacity/total lung capacity ratio. Int J Chron Obstruct Pulmon Dis. 2018;13:1105–1113. doi:10.2147/COPD.S155848
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796. doi:10.1016/S0140-6736(07)61382-8
   PubMed Web of Science ®Google Scholar
• Hasani A, Chapman TH, McCool D, Smith RE, Dilworth JP, and Agnew JE. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. Chron Respir Dis. 2008;5(2):81–86. doi:10.1177/1479972307087190
   PubMedGoogle Scholar
• Nishimura M. High-flow nasal cannula oxygen therapy in adults: physiological benefits, indication, clinical benefits, and adverse effects. Respir Care. 2016;61(4):529–541. doi:10.4187/respcare.04577
   PubMed Web of Science ®Google Scholar
• Roca O, Hernandez G, Diaz-Lobato S, et al. Current evidence for the effectiveness of heated and humidified high flow nasal cannula supportive therapy in adult patients with respiratory failure. Crit Care. 2016;20(1):109. doi:10.1186/s13054-016-1263-z
   PubMedGoogle Scholar
• Storgaard LH, Weinreich UM, Laursen BS. COPD patients’ experience of long-term domestic oxygen-enriched nasal high flow treatment: a qualitative study. COPD. 2020;17(2):175–183. doi:10.1080/15412555.2020.1736998
   PubMedGoogle Scholar
• Pilcher J, Eastlake L, Richards M, et al. Physiological effects of titrated oxygen via nasal high-flow cannulae in COPD exacerbations: a randomized controlled cross-over trial. Respirology. 2017;22(6):1149–1155. doi:10.1111/resp.13050
   PubMed Web of Science ®Google Scholar
• Rea H, McAuley S, Jayaram L, et al. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med. 2010;104(4):525–533. doi:10.1016/j.rmed.2009.12.016
   PubMed Web of Science ®Google Scholar
• Storgaard LH, Hockey HU, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis. 2018;13:1195–1205. doi:10.2147/COPD.S159666
   PubMed Web of Science ®Google Scholar
• Milne RJ, Hockey H, Rea H. Long-term air humidification therapy is cost-effective for patients with moderate or severe chronic obstructive pulmonary disease or bronchiectasis. Value Health. 2014;17(4):320–327. doi:10.1016/j.jval.2014.01.007
   PubMed Web of Science ®Google Scholar
• Papanicolas I, Woskie LR, Jha AK. Health care spending in the United States and other high-income countries. JAMA. 2018;319(10):1024–1039. doi:10.1001/jama.2018.1150
   PubMed Web of Science ®Google Scholar
• Anderlini D. The United States health care system is sick: from Adam Smith to overspecialization. Cureus. 2018;10(5):e2720. doi:10.7759/cureus.2720
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-Effectiveness in Health and Medicine. Oxford University Press; 2016.
   Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103. doi:10.1001/jama.2016.12195
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Int J Technol Assess Health Care. 2013;29(2):117–122. doi:10.1017/S0266462313000160
   PubMed Web of Science ®Google Scholar
• Briggs AH, Baker T, Risebrough NA, et al. Development of the galaxy chronic obstructive pulmonary disease (COPD) model using data from ECLIPSE: internal validation of a linked-equations cohort model. Med Decis Making. 2017;37(4):469–480. doi:10.1177/0272989X16653118
   PubMed Web of Science ®Google Scholar
• Risebrough NA, Briggs A, Baker TM, et al. Validating A model to predict disease progression outcomes in patients with COPD. Value Health. 2014;17(7):A560–A561. doi:10.1016/j.jval.2014.08.1852
   PubMed Web of Science ®Google Scholar
• Khoudigian-Sinani S, Kowal S, Suggett JA, Coppolo DP. Cost-effectiveness of the Aerobika* oscillating positive expiratory pressure device in the management of COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2017;12:3065–3073. doi:10.2147/COPD.S143334
   PubMed Web of Science ®Google Scholar
• Thanh NX, Jacobs P, Suggett J, McIvor A, Kaplan A. Cost-effectiveness of the Aerobika(R) oscillating positive expiratory pressure device in the management of chronic obstructive pulmonary disease exacerbations in Canada. Can Respir J. 2019;2019:9176504. doi:10.1155/2019/9176504
   PubMed Web of Science ®Google Scholar
• Caro JJ, Briggs AH, Siebert U, Kuntz KM; Force I-SMGRPT. Modeling good research practices--overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15(6):796–803. doi:10.1016/j.jval.2012.06.012
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-Effectiveness in Health and Medicine. 2nd ed. New York, NY: Oxford University Press; 2017.
   Google Scholar
• McArdle N, Devereux G, Heidarnejad H, Engleman HM, Mackay TW, Douglas NJ. Long-term use of CPAP therapy for sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med. 1999;159(4 Pt 1):1108–1114. doi:10.1164/ajrccm.159.4.9807111
   PubMed Web of Science ®Google Scholar
• Dhamane AD, Witt EA, Su J. Associations between COPD severity and work productivity, health-related quality of life, and health care resource use: a cross-sectional analysis of national survey data. J Occup Environ Med. 2016;58(6):e191–e197. doi:10.1097/JOM.0000000000000735
   PubMed Web of Science ®Google Scholar
• Chandra K, Blackhouse G, McCurdy BR, et al. Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model. Ont Health Technol Assess Ser. 2012;12(12):1–61.
   Google Scholar
• Lacasse Y, Bernard S, Martin S, Boivin M, Maltais F. Utility scores in patients with oxygen-dependent COPD: a case-control study. COPD. 2015;12(5):510–515. doi:10.3109/15412555.2014.995290
   PubMedGoogle Scholar
• Borg S, Ericsson A, Wedzicha J, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health. 2004;7(2):153–167. doi:10.1111/j.1524-4733.2004.72318.x
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health. 2005;8(1):32–46. doi:10.1111/j.1524-4733.2005.03086.x
   PubMed Web of Science ®Google Scholar
• Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US. Int J Chron Obstruct Pulmon Dis. 2018;13:3867–3877. doi:10.2147/COPD.S177097
   PubMed Web of Science ®Google Scholar
• Samyshkin Y, Schlunegger M, Haefliger S, Ledderhose S, Radford M. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. Int J Chron Obstruct Pulmon Dis. 2013;8:79–87. doi:10.2147/COPD.S37486
   PubMed Web of Science ®Google Scholar
• Fisher Paykel, Inc. Cost of MyAirvo HFNC Device - Personal Communication. Fisher Paykel, Inc; 2021.
   Google Scholar
• Medical Expenditure Panel Survey - Insurance Component. Agency for healthcare research and quality; 2018. Available from: https://meps.ahrq.gov/mepstrends/hc_use/. Accessed March 7, 2023.
   Google Scholar
• US Department of Labor. Bureau of labor statistics. Occupational Outlook Handbook; 2020. Available from: https://www.bls.gov/ooh/healthcare/respiratory-therapists.htm. Accessed November 3, 2021.
   Google Scholar
• Dalal AA, Shah M, D’Souza AO, Rane P. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med. 2011;105(3):454–460. doi:10.1016/j.rmed.2010.09.003
   PubMed Web of Science ®Google Scholar
• King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making. 2005;25(6):667–677. doi:10.1177/0272989X05282640
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797. doi:10.1056/NEJMp1405158
   PubMed Web of Science ®Google Scholar
• Tice JA, Kumar V, Otounye I, et al. Cognitive and Mind-Body Therapies for Chronic Low Back and Neck Pain: Effectiveness and Value. Institute for Clinical and Economic Review; 2017.
   Google Scholar
• Jing G, Li J, Hao D, et al. Comparison of high flow nasal cannula with noninvasive ventilation in chronic obstructive pulmonary disease patients with hypercapnia in preventing postextubation respiratory failure: a pilot randomized controlled trial. Res Nurs Health. 2019;42(3):217–225. doi:10.1002/nur.21942
   PubMed Web of Science ®Google Scholar
• Storgaard LH, Hockey HU, Weinreich UM. Development in PaCO2 over 12 months in patients with COPD with persistent hypercapnic respiratory failure treated with high-flow nasal cannula-post-hoc analysis from a randomised controlled trial. BMJ Open Respir Res. 2020;7:1. doi:10.1136/bmjresp-2020-000712
   Web of Science ®Google Scholar
• Tan D, Walline JH, Ling B, et al. High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial. Crit Care. 2020;24(1):489. doi:10.1186/s13054-020-03214-9
   PubMed Web of Science ®Google Scholar
• Sorensen SS, Storgaard LH, Weinreich UM. Cost-effectiveness of domiciliary high flow nasal cannula treatment in COPD patients with chronic respiratory failure. Clinicoecon Outcomes Res. 2021;13:553–564. doi:10.2147/CEOR.S312523
   PubMed Web of Science ®Google Scholar
• Milne RJ, Hockey HU, Garrett J. Hospital cost savings for sequential COPD patients receiving domiciliary nasal high flow therapy. Int J Chron Obstruct Pulmon Dis. 2022;17:1311–1322. doi:10.2147/COPD.S350267
   PubMed Web of Science ®Google Scholar
• Starkie HJ, Briggs AH, Chambers MG, Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011;14(2):354–360. doi:10.1016/j.jval.2010.09.011
   PubMed Web of Science ®Google Scholar
• Chao KY, Liu WL, Nassef Y, Tseng CW, Wang JS. Effects of high-flow nasal cannula with oxygen on self-paced exercise performance in COPD: a randomized cross-over trial. Medicine. 2021;100(51):e28032. doi:10.1097/MD.0000000000028032
   PubMed Web of Science ®Google Scholar
• Piquilloud L, Olivier PY, Richard JC, et al. High flow nasal cannula improves breathing efficiency and ventilatory ratio in COPD patients recovering from an exacerbation. J Crit Care. 2022;69:154023. doi:10.1016/j.jcrc.2022.154023
   PubMed Web of Science ®Google Scholar
• Squires DA. Explaining high health care spending in the United States: an international comparison of supply, utilization, prices, and quality. Issue Brief. 2012;10:1–14.
   Google Scholar